PFE
Pfizer, Inc.
Drug Manufacturers - General · Healthcare · United States
29.95
close · 2026-10-29
value
83
cheaper than peers83
quality
61
stronger fundamentals61
ranked against
Healthcare
value
quality
547 peerssector comparisonwide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 10.38× | 82 |
| EV to EBITDA | 7.93× | 79 |
| price to book | 2.00× | 68 |
| price to sales | 2.39× | 65 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 27.9% | 93 |
| return on equity | 5.0% | 75 |
| revenue growth | 2.6% | 32 |
| debt to equity | 74.3% | 31 |
4 of 4 measures available
Facts
| market cap | $171B |
| free cash flow | $12.49B |
| employees | 75,000 |
| first trade | 1972-06-01 |
| next earnings | 2026-11-03 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 1.36 | 1.41 | 0.37 | 5.47 |
| free cash flow | $9.07B | $9.84B | $4.79B | $26.03B |
| net income | $7.77B | $8.03B | $2.12B | $31.37B |
| revenue | $62.58B | $63.63B | $59.55B | $101.17B |
| unusual items | -$8.96B | -$4.58B | -$4.35B | -$4.01B |